全球結合疫苗市場規模（按類型、適應症、病原體、患者類型、地區、範圍和預測）

結合疫苗市場規模及預測

結合疫苗市場規模預計在 2024 年達到 167 億美元，到 2032 年將達到 382.7 億美元，2026 年至 2032 年的複合年成長率為 11%。

• 結合疫苗是次單位疫苗，專門設計用於針對細菌表面的弱抗原產生更強的免疫反應。
• 結合疫苗可以誘導免疫記憶並減少無症狀性的細菌攜帶者，從而產生大量的群體免疫。
• 目前已利用肺炎鏈球菌多醣體開發了結合疫苗，其中7價、9價甚至11價疫苗已進入臨床試驗階段；針對A群和C群腦膜炎球菌的結合疫苗也正在研發中，但針對B群腦膜炎雙球菌的結合疫苗仍存在挑戰。
• 結合疫苗有三種：C群腦膜炎雙球菌結合疫苗（MnCC）、b型流感嗜血桿菌結合疫苗（Hib）和肺炎鏈球菌結合疫苗（PnC）。
• 肺炎鏈球菌結合疫苗可以預防引起肺炎鏈球菌疾病的細菌。肺炎鏈球菌結合疫苗有三種：PCV13、PCV15 和 PCV20。

全球結合疫苗市場動態

關鍵市場促進因素

• 嬰幼兒早期保護：改善啟動免疫是其主要優點之一。與傳統免疫接種不同，結合疫苗能夠更好地在免疫系統尚在發育的新生兒和幼兒中引發免疫反應（即抗體反應，尤其是IgG1抗體）。這使得在關鍵發育階段能夠更早預防疾病。
• 持久免疫力和增強免疫力：含有結合物的疫苗能夠有效活化免疫系統的記憶。它們能夠刺激長壽記憶B細胞的增殖。即使多年後再次接觸同一種細菌，這些記憶B細胞也能記住特定抗原，並立即產生強烈的免疫反應。如果您再次接種疫苗，這將起到增強免疫力的作用。
• 黏膜保護：除了常規疫苗主要針對的血流抗體生成外，結合疫苗還能誘發分泌型IgA和黏膜活性IgG抗體的合成。黏膜表面是人體抵抗多種疾病的第一道防線，而這些特化抗體對此防禦至關重要。
• 更佳療效和精準標靶：結合疫苗促進「親和性成熟」過程，這意味著免疫系統逐漸提高抗體的產生能力，從而提高抗體對目標抗原的親和性（結合更緊密）。更緊密的結合增強了抗體的調理作用，標記出細菌以便免疫細胞清除，從而提高疫苗的有效性。
• 顯著減少Hib和肺炎球菌性腦膜炎：目前，針對PCV和Hib（b型流感嗜血桿菌）的疫苗接種在預防兒童腦膜炎方面非常有效。結合疫苗接種在促進群體免疫方面發揮了重要作用，因為它減少了持有病菌但無症狀的人數。這意味著即使未接種疫苗的人也能受到保護，因為帶因者人數減少意味著人口感染風險降低。
• 急性中耳炎和社區型肺炎發生率增加：這些疫苗具有廣泛的功效，不僅可以預防腦膜炎和敗血症等危險且侵襲性的疾病，還能有效治療常見的良性疾病。接種結合疫苗可顯著降低成人和兒童急性中耳炎（耳部感染疾病）和社區型肺炎的發生率。這些結果表明，未來最佳化預防策略可能會使社區更加健康。肺炎鏈球菌性肺炎每年在美國導致15萬人住院，死亡率為5-7%。

主要挑戰

• 成本與可負擔性：結合疫苗的研發和生產成本通常高於傳統疫苗。這些成本的增加導致每劑疫苗價格上漲，這可能會限制其在新興國家的普及。此外，結合疫苗等現代昂貴疫苗成本過高且研發不足，無法由政府資金承擔，新興國家無力負擔研發和購買疫苗的費用。
• 基礎設施有限且低溫運輸挑戰：有效分發結合疫苗需要強大的低溫運輸基礎設施，以確保整個供應鏈的儲存溫度適宜。在南非、中東和亞洲等資源和基礎設施有限的地區，這可能是一個嚴重的問題，導致疫苗劣化和效力降低。例如，在印度，1-59個月齡兒童的肺炎死亡率為12%，嬰兒肺炎死亡率為3%。
• 公眾認知與疫苗猶豫：錯誤訊息和疫苗接種疑慮可能會阻礙結合疫苗的接種。透過教育和宣傳宣傳活動解決公眾擔憂，對於消除疫苗猶豫並確保盡可能高的接種率至關重要。
• 不斷變化的細菌血清型和菌株：某些細菌，例如肺炎鏈球菌，具有不同的血清型和菌株。儘管結合疫苗針對的是特定的血清型，但疫苗無法預防的新發或新菌株仍構成危險。為了應對這個問題，研究人員必須持續開發針對新型血清型或具有更廣泛效力的疫苗。例如，大約75%的侵襲性肺炎球菌疾病和83%的肺炎球菌腦膜炎病例發生在兒童身上。

主要趨勢：

• 改善兒童免疫接種計劃的需求不斷成長：市場需求的驅動力源於人們對結合疫苗益處的認知不斷加深，尤其是其保護嬰幼兒免受致命感染疾病的能力。低度開發國家對改善兒童免疫系統的日益關注，為市場成長開闢了新的途徑。例如，在印度，到2020年，約90%的兒童將能夠接種救命疫苗。
• 擴大疫苗靶向：研發目標是開發能夠應對更多種類感染疾病的結合疫苗。這包括持續研發免疫接種，以預防由不同腦膜炎球菌菌株和新型肺炎球菌血清型引起的腦膜炎等疾病。
• 技術發展：改進的疫苗生產方法正在創造更有效、更實惠的結合疫苗。這可能會使疫苗更容易取得且價格更實惠，尤其是在資源有限的地區。借助基因編輯等新技術，可以開發出具有更高免疫抗原性或更廣泛保護作用的新型結合疫苗。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 結合疫苗市場（按類型）

• 單價結合疫苗
• 多效價結合疫苗

5. 結合疫苗市場（按適應症）

• 肺炎球菌
• 流感
• 百白破疫苗
• 腦膜炎奈瑟菌
• 傷寒

6. 結合疫苗市場（依病原體類型）

• 細菌結合疫苗
• 病毒結合疫苗
• 聯合（病毒和細菌）疫苗

7. 結合疫苗市場（依患者類型）

• 孩子們
• 成人

第8章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第9章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第10章 競爭格局

• 主要企業
• 市場佔有率分析

第11章 公司簡介

• Bharat Biotech
• Biological E
• CSL Limited
• Glaxo SmithKline, plc.
• Merck and Company
• Bio-Rad
• Novartis AG
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India

第12章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第13章 附錄

• 簡稱列表
• 來源和參考文獻

Conjugate Vaccine Market Size And Forecast

Conjugate Vaccine Market size was valued at USD 16.7 Billion in 2024 and is projected to reach USD 38.27 Billion by 2032, growing at a CAGR of 11% from 2026-2032.

• A conjugate vaccine is a subunit vaccine that is designed to elicit a stronger immune response against weak antigens, especially those found on the surface of bacteria.
• The conjugate vaccine is capable of substantially eliciting herd immunity by inducing immunological memory and lowering the bacteria's asymptomatic carriage.
• Conjugate vaccines are being developed using pneumococcal polysaccharides, with 7, 9, and even 11-valent versions undergoing clinical trials, and conjugate vaccines targeting meningococcal groups A and C, but the group B meningococcal presents a challenge.
• Conjugate vaccines are available in three types Meningococcal Group C Conjugate (MnCC), Hemophilus Influenzae Type b (Hib), and Pneumococcal Conjugate (PnC).
• Pneumococcal conjugate vaccine helps protect against bacteria that cause pneumococcal disease. There are three pneumococcal conjugate vaccines (PCV13, PCV15, and PCV20).

Global Conjugate Vaccine Market Dynamics

The key market dynamics that are shaping the global Conjugate Vaccine Market include:

Key Market Drivers

• Early Protection for Infants: Improved priming is one of the main benefits. Contrary to some conventional vaccinations, conjugate vaccines can successfully elicit an immune response in newborns and young children whose immune systems are still developing (i.e., an antibody response, specifically IgG1 antibodies). This enables earlier illness prevention throughout crucial developmental phases.
• Long-Term Immunity & Booster Effect: Vaccines containing conjugates are excellent at igniting the memory of the immune system. They encourage the growth of memory B cells with a long lifespan. When the same germs are encountered again, even years later, these memory cells can quickly mount a potent immune response because they can recall the particular antigen. When obtaining a revaccination, this translates to a booster effect that strengthens immunity even more.
• Mucosal Protection: Conjugate vaccines can induce secretory IgA and mucosally active IgG antibody synthesis, in addition to the bloodstream antibody production that is the main target of traditional vaccines. Mucosal surfaces are the body's first line of defense against numerous illnesses, and these particular antibodies are essential for their protection.
• Better Effectiveness and Precise Targeting: Conjugate vaccinations encourage the "affinity maturation" process. This indicates that as a result of the immune system's gradual improvement in antibody production, the resulting antibodies have a higher affinity (tighter binding) to the target antigen. The opsonizing function, in which antibodies mark bacteria for eradication by immune cells, is improved by this closer match, thus increasing the vaccine's efficacy.
• Significant Reduction in Hib and Pneumococcal Meningitis: The current vaccinations against PCV and Hib (Haemophilus Influenzae type b) are exceptionally successful in avoiding childhood meningitis. Conjugate vaccinations play a major role in promoting herd immunity by lowering the number of people who carry bacteria but do not exhibit any symptoms. This implies that even individuals who have not received vaccinations are protected since fewer carriers equate to a lower risk of transmission within the population.
• Rising Incidence of Acute Otitis Media and Community-Acquired Pneumonia: These vaccines have far-reaching effects that go well beyond shielding against dangerous, invasive illnesses like meningitis and sepsis. They are incredibly successful in treating common benign ailments. Conjugate vaccinations considerably lower the incidence of acute otitis media (ear infections) and community-acquired pneumonia in both adults and children. These results pave the way for promising future prevention strategy optimizations that could result in even healthier communities. In the United States every year 150,000 people are hospitalized for Pneumococcal pneumonia and the mortality rate is 5%-7%.

Key Challenges:

• Cost and Affordability: Compared to regular vaccines, conjugate vaccines are frequently more expensive to research and produce. This increased expense may result in a higher price per dosage, which can restrict accessibility in emerging countries. In addition, the expense of more recent and costly vaccines, such as conjugate vaccines, are not covered by government funding as the vaccines are expensive and underdeveloped, and developing countries cannot afford the cost of vaccine research and purchase.
• Limited Infrastructure and Cold Chain Challenges: To ensure appropriate storage temperatures across the supply chain, effective conjugate vaccine delivery necessitates a strong cold chain infrastructure. In areas with inadequate resources or infrastructure, such the regions like South Africa, and Middle East, and Asia this can pose a serious problem and result in vaccine deterioration and decreased efficacy, which is expected to hamper the growth of the Conjugate Vaccine Market in the underdeveloped and developing regions. For instance, the mortality rate in developing regions is increasing, such as in India children with age 1-59 months affected by pneumonia have a 12% mortality rate, and infants affected have a 3% mortality rate.
• Public Perception and Vaccine Hesitancy: The widespread use of conjugate vaccines may be hampered by misinformation and skepticism about vaccinations. To combat vaccine hesitancy and guarantee the highest possible immunization rates, it is imperative to address public concerns through campaigns of education and awareness.
• Changing Bacterial Serotypes and Strains: Some bacteria, such as pneumococcus, have different serotypes and strains. Conjugate vaccinations target particular serotypes, but emerging or novel strains that are not protected by the vaccine can still be dangerous. To remain ahead of this problem, researchers must continue to create vaccinations that target novel serotypes or vaccines with a wider spectrum of effects. For instance, about 75% of invasive pneumococcal disease and 83% of pneumococcal meningitis occur in children.

Key Trends:

• Growing Demand for Better Childhood Immunization Programs:Demand in the market is being driven by rising knowledge of the advantages of conjugate vaccinations, particularly their capacity to protect young infants against deadly infections. Growing attention to improving childhood immunization systems in underdeveloped nations opens up new avenues for market growth. For instance, in India around 90% of children have access to life-saving vaccines till 2020.
• Increased Vaccine Targets: The goal of research and development is to create conjugate vaccines that can combat a larger variety of infections. This involves the continuous creation of vaccinations to prevent illnesses like meningitis brought on by different meningococcal strains and novel pneumococcal serotypes.
• Technological Developments: More effective and reasonably priced conjugate vaccines are being created as a result of improvements in vaccine production methods. This could increase accessibility and affordability, especially in environments with limited resources. Novel combination vaccines with enhanced immunogenicity or wider protection could be developed with the help of emerging technologies like gene editing.

Global Conjugate Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Conjugate Vaccine Market:

North America

• North America is known for its fast-paced atmosphere, which facilitates the rapid adoption of vaccination breakthroughs. This flexibility makes it possible to increase the development of vaccines and investigate novel solutions with more ease. This is in contrast to certain regions of Europe and Asia where adoption rates may be lower.
• Public healthcare systems that are well-developed and provide extensive coverage for medical services are found throughout North America. Strong assistance is extended to vaccine research and development (R&D) endeavors. This encourages creativity and concentrates attention on enhancing public health via immunization campaigns. For instance, in the U.S. in 2022 around 9% of children ages 6 months to 17 years have been vaccinated by influenza vaccination during the past 12 months.
• An established healthcare system and the existence of large pharmaceutical companies offer a solid basis for the conjugate vaccination industry in North America. The region's supremacy in this sector is mostly due to these factors. For instance, in 2021, the United States spent around 17.8 & of the gross domestic product on healthcare.
• The increasing prevalence of influenza in the U.S. is propelling the growth of the Conjugate Vaccine Market. For instance, in 2023 around 121 children died due to influenza. According to the Centers for Disease Control and Prevention, at least 30 Million people are affected 340,00 are hospitalized, and 21,000 deaths due to the flu.

Asia-Pacific

• Asia-Pacific is the fastest-growing region in the Conjugate Vaccine Market during the forecast period due to the increasing population and government initiatives for healthcare infrastructure.
• In Asia-Pacific, the population is expanding quickly in many of the member states. This generates a great deal of demand, especially for youngsters, for greater vaccination coverage. Given their efficacy in defending young infants, conjugate vaccinations are ideally positioned to meet this requirement.
• For instance, in India in 2022-23 cases reported of pneumonia in the states are Maharashtra (14078), Assam (11011), Jammu and Kashmir (4952), Madhya Pradesh (39948), Punjab (14965) etc.
• Increasing the prevalence of conjugate vaccines the government is actively taking initiatives such as funding immunization campaigns and investment in research and development. For instance, in India from 2015 to 2020 the immunization coverage in children from the age of 12-23 months is estimated to be 62% in 2015-2016 to 76% in 2019-2020.

Global Conjugate Vaccine Market: Segmentation Analysis

The Global Conjugate Vaccine Market is segmented on the basis of Type, Disease Indication, Pathogen Type, Patient Type, and Geography.

Conjugate Vaccine Market, By Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

Based on Type, the market is segmented into Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine. The Multivalent Conjugate Vaccines segment is substantially leading in the Conjugate Vaccine Market and is expected to continue its growth during the forecast period. A significant breakthrough in the battle against infectious illnesses has been made with the development of multivalent conjugate vaccines. Their capacity to offer more comprehensive protection, economy, and effectiveness is propelling market expansion and clearing the path for a healthier future. Technological developments along with encouraging policy measures from the government will probably ensure that multivalent conjugate vaccines continue to dominate the conjugate vaccine industry.

Conjugate Vaccine Market, By Disease Indication

• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Typhoid

Based on Disease Indication, the market is segmented into Pneumococcal, Influenza, DTP, Meningococcal, and Typhoid. The increasing prevalence of DTP in children globally is fueling the growth of DTP vaccines all over the world. For instance, in 2022, around 86% and in 2021 around 89% the coverage of DTPcv1 has increased globally and similarly the coverage of DTPcv3 has increased from 81% in 2021 and 84% in 2022. To ensure that children everywhere have a healthier future, ongoing initiatives to increase vaccination rates, broaden immunization programs, and discover novel vaccines are essential. DTP vaccine segments in the Conjugate Vaccine Market emphasize how important these vaccinations are in shielding kids from potentially fatal diseases.

Conjugate Vaccine Market, By Pathogen Type

• Bacterial Conjugate Vaccine
• Viral Conjugate Vaccine
• Combination (Viral And Bacterial) Conjugate Vaccine

Based on Pathogen Type, the market is segmented into Bacterial Conjugate Vaccine, Viral Conjugate Vaccine, and Combination (Viral And Bacterial) Conjugate Vaccine. Bacterial Conjugate Vaccine is significantly leading the Conjugate Vaccine Market. These vaccinations target bacteria specifically, which is a single-celled organism that can cause a variety of diseases. Bacterial conjugate vaccines directly target the bacteria, in contrast to toxoid vaccinations, which concentrate on inactivated bacterial toxins.

Conjugate Vaccine Market, By Patient Type

• Pediatric
• Adults

Based on Patient Type, the market is segmented into Pediatric and Adults. Pediatric segment is substantially leading in the Conjugate Vaccine Market. Hib meningitis is a severe infection that can be fatal for young children. The Hib conjugate vaccine has significantly reduced the burden of this disease. In children, pneumococcal bacteria are the primary cause of sepsis, meningitis, and pneumonia. PCV vaccinations provide essential defense against several infections.

Key Players

The "Global Conjugate Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bharat Biotech, Biological E, CSL Limited, Glaxo SmithKline, plc., Merck and Company, Bio-Rad, Novartis AG, Pfizer Inc., Sanofi Pasteur, and Serum Institute of India. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Conjugate Vaccine Market Recent Developments
• In August 2022, Nigeria announced a vaccine of Bharat Biotech for the immunization of children. Reducing the infectious disease burden amongst children in the developing world, and ensuring nations like Nigeria in the African continent, have access to cost-effective world-class interventions for infants and vulnerable populations. ROTAVAC(R) is safe and effective at preventing diarrheal disease caused by the Rotavirus."
• In July 2023, the Serum Institute of India announced the first conjugate vaccine that protects from the predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive(R) is a vaccine that protects against meningococcal serogroups A, C, W, Y, and X. It was developed over 13 years of collaboration between Serum Institute of India Pvt. Ltd. and PATH, with significant funding from the Foreign, Commonwealth and Development Office of the UK government.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Conjugate Vaccine Market, By Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

5. Conjugate Vaccine Market, By Disease Indication

• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Typhoid

6.Conjugate Vaccine Market, By Pathogen Type

• Bacterial Conjugate Vaccine
• Viral Conjugate Vaccine
• Combination (Viral And Bacterial) Conjugate Vaccine

7.Conjugate Vaccine Market, By Patient Type

• Pediatric
• Adults

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Bharat Biotech
• Biological E
• CSL Limited
• Glaxo SmithKline, plc.
• Merck and Company
• Bio-Rad
• Novartis AG
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References